Abstract

Natalizumab therapy in multiple sclerosis (MS) is associated with risk for progressive multifocal leukoencephalopathy (PML) from the John Cunningham

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call